If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,554.00    30.00 (1.97%)
Bid:
1,561.00
Ask:
1,564.00
Spread: 3.00 (0.192%)
Market Cap: £3.27b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

LTIP Awards

30 Apr 2008 15:22

Hikma Pharmaceuticals Plc30 April 2008 Hikma Pharmaceuticals PLC - LTIP Awards LONDON, 30 April 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)announces that the Remuneration Committee has made the following nil-cost awardsunder the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP")to Directors and Persons Discharging Managerial Responsibility ("PDMRs") of theCompany. Awards under the LTIP were made on 29 April 2008 at a price of Β£4.64 perordinary share as follows:- Name of Director/PDMR Number of LTIP SharesSaid Darwazah 90,000Mazen Darwazah 54,000Bassam Kanaan 54,000Taghreed Al-Shunnar 54,000Majda Labadi 54,000Nabil Rizk 54,000 The shares subject to the LTIP awards will only be released to the participantsin three years time, subject to their continued employment and the satisfactionof the comparative Total Shareholder Return ("TSR") performance target.Participants will only receive the full benefit of their share incentives if TSRperformance against the Comparator Group is at least at the upper quartile. - ENDS -Enquiries: Hikma Pharmaceuticals PLCHenry Knowles +44 20 7399 2760Company Secretary Susan Ringdal +44 20 7399 2760Investor Relations Director About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and"Generics". Hikma's operations are based principally in the Middle East andNorth Africa ("MENA") region, where it is a market leader and sells across 17countries, the United States and Europe. In 2007, the Group achieved revenuesof $449 million (2006 $317 million) and profit attributable to shareholders was$63 million (2006 $55 million). For news and other information, please visitwww.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Feb 201712:47 pmRNSHolding(s) in Company
18th Jan 20179:11 amRNSHikma receives approval for Sodium Oxybate
20th Dec 20163:24 pmRNSDirector/PDMR Shareholding
20th Dec 201611:00 amRNSHolding(s) in Company
20th Dec 201610:47 amRNSDirector/PDMR Shareholding
13th Dec 20161:46 pmRNSDirector/PDMR Shareholding
12th Dec 20164:06 pmRNSDirector/PDMR Shareholding
7th Dec 20169:35 amRNSDirector/PDMR Shareholding
6th Dec 20166:04 pmRNSTotal Voting Rights
5th Dec 201612:34 pmRNSDirector/PDMR Shareholding
2nd Dec 20165:42 pmRNSDirector/PDMR Shareholding
28th Nov 20169:59 amRNSDirector/PDMR Shareholding
22nd Nov 20167:00 amRNSHikma announces agreement with Vectura
16th Nov 201611:12 amRNSAdditional Listing
11th Nov 20162:48 pmRNSTotal Voting Rights
10th Nov 20167:00 amRNSTrading Statement
3rd Oct 20164:37 pmRNSBlock listing Interim Review
28th Sep 20165:12 pmRNSDirector/PDMR Shareholding
28th Sep 20169:09 amRNSDirector/PDMR Shareholding
26th Sep 201610:18 amRNSDirector/PDMR Shareholding
22nd Sep 20163:35 pmRNSDirector/PDMR Shareholding
20th Sep 20167:00 amRNSBoard appointment and succession
16th Sep 20165:32 pmRNSDirector/PDMR Shareholding
15th Sep 20164:36 pmRNSDirector/PDMR Shareholding
8th Sep 20165:18 pmRNSDirector/PDMR Shareholding
6th Sep 20165:52 pmRNSDirector/PDMR Shareholding
6th Sep 20164:02 pmRNSTotal Voting Rights
1st Sep 201610:18 amRNSDirector/PDMR Shareholding
26th Aug 20164:28 pmRNSDirector/PDMR Shareholding
26th Aug 20169:47 amRNSDirector/PDMR Shareholding
24th Aug 20167:00 amRNSHalf-year Report
10th Aug 20169:22 amRNSNotice of Results
3rd Aug 20165:18 pmRNSTrading Statement
21st Jul 20167:00 amRNSRegulatory approval of Hikma's colchicine upheld
20th Jul 20167:00 amRNSLaunch of Generic Xeloda® Tablets in the US
27th Jun 20167:01 amRNSDirector/PDMR Shareholding
27th Jun 20167:00 amRNSTotal Voting Rights
20th Jun 20167:00 amRNSDirector/PDMR Shareholding
7th Jun 20164:44 pmRNSTotal Voting Rights
24th May 20167:00 amRNSDirector/PDMR Shareholding
19th May 201612:15 pmRNSFurther re Colchicine Litigation
19th May 201610:17 amRNSDirector/PDMR Shareholding
18th May 20164:25 pmRNSDirector/PDMR Shareholding
12th May 20163:14 pmRNSResult of AGM
12th May 20167:00 amRNSAGM Statement
9th May 20164:05 pmRNSDirector/PDMR Shareholding
6th May 20169:12 amRNSDoc re. Bond Guarantor Group
29th Apr 20165:40 pmRNSDirector/PDMR Shareholding
28th Apr 20162:58 pmRNSDirector/PDMR Shareholding
25th Apr 20164:19 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.